EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Head And Neck Cancer. According to GlobalData, Phase II drugs for Head And Neck Cancer have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EEDVD-682’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EEDVD-682 overview

EEDVD-682 is under development for treatment of solid tumors including bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, melanoma, non-small cell lung cancer (NSCLC) and pancreatic cancer. The drug candidate is administered intravenously. It consists of EDV nanocells filled with a payload called PNU-159682 (PNU-682). These payload-packaged EDVs are coated with a antibody which targets epidermal growth factor receptor (EGFR). It is based on EnGeneIC s bacterially-derived EDV nanocell platform.

ImmunityBio overview

ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.

For a complete picture of EEDVD-682’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.